HALIFAX, March 3, 2014 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid testing technologies and solutions, reported today that the Company's Board of Directors, Corporate Secretary, and Chief Financial Officer have been granted options to purchase common shares under its Stock Option Plan approved at the Company's Annual General Meeting held on January 25, 2013. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto, Mr. Markus Meile and Ms. Robyn Cook were granted a total of 1,350,000 options at an exercise price of $0.10 per share and exercisable for a period of two years ending March 2, 2016. These individuals, as well as Dr. Michael Sidler and Mr. Jelle Kuypers, were granted a total of 1,500,000 options at an exercise price of $0.10 per share and exercisable for a period of three years, ending March 2, 2017.
MedMira is a leading developer and manufacturer of rapid testing technology and solutions. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad™ brands in global markets. MedMira's patented Rapid Vertical Flow Technology™ is the platform the Company's rapid testing solutions are built on including its rapid HIV test which is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MedMira Inc.
For further information:
Andrea Young, Corporate Communications